Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pinuccia Valagussa

Showing results (21-30 of 58) with videos related to

Pageof 6
Sort By:
Cancer|March 20, 2002
Ten-year survival with chemotherapy and radiotherapy in patients with squamous cell carcinoma of the esophagusPaolo Bidoli, Emilio Bajetta, Simonetta C Stani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2003
HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancerAngela Moliterni, Sylvie Ménard, Pinuccia Valagussa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2003
Primary chemotherapy in resectable oral cavity squamous cell cancer: a randomized controlled trialLisa Licitra, Cesare Grandi, Marco Guzzo, et al.
Cancer Science|February 6, 2010
Recurrence and mortality dynamics for breast cancer patients undergoing mastectomy according to estrogen receptor status: different mortality but similar recurrenceRomano Demicheli, Elia Biganzoli, Ilaria Ardoino, et al.
The Lancet. Oncology|January 13, 2018
Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 studyLuca Gianni, Giancarlo Bisagni, Marco Colleoni, et al.
Leukemia & Lymphoma|June 10, 2010
Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma: a single institution experienceSimonetta Viviani, Massimo Di Nicola, Valeria Bonfante, et al.
NPJ Breast Cancer|January 11, 2022
Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancerLuca Gianni, Marco Colleoni, Giancarlo Bisagni, et al.
The Breast Journal|February 28, 2019
Single Institution trial of anthracycline- and taxane-based chemotherapy for operable breast cancer: The ASTER studyGabriella Mariani, Giulia Galli, Stefano Cavalieri, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 13, 2012
Bortezomib plus dexamethasone followed by escalating donor lymphocyte infusions for patients with multiple myeloma relapsing or progressing after allogeneic stem cell transplantationVittorio Montefusco, Francesco Spina, Francesca Patriarca, et al.
Blood|May 10, 2003
Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myelomaPaolo Corradini, Michele Cavo, Henk Lokhorst, et al.
Pageof 6

Showing results (21-30 of 58) with videos related to

Sort By:
Pageof 6
Cancer|March 20, 2002
Ten-year survival with chemotherapy and radiotherapy in patients with squamous cell carcinoma of the esophagusPaolo Bidoli, Emilio Bajetta, Simonetta C Stani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2003
HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancerAngela Moliterni, Sylvie Ménard, Pinuccia Valagussa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2003
Primary chemotherapy in resectable oral cavity squamous cell cancer: a randomized controlled trialLisa Licitra, Cesare Grandi, Marco Guzzo, et al.
Cancer Science|February 6, 2010
Recurrence and mortality dynamics for breast cancer patients undergoing mastectomy according to estrogen receptor status: different mortality but similar recurrenceRomano Demicheli, Elia Biganzoli, Ilaria Ardoino, et al.
The Lancet. Oncology|January 13, 2018
Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 studyLuca Gianni, Giancarlo Bisagni, Marco Colleoni, et al.
Leukemia & Lymphoma|June 10, 2010
Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma: a single institution experienceSimonetta Viviani, Massimo Di Nicola, Valeria Bonfante, et al.
NPJ Breast Cancer|January 11, 2022
Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancerLuca Gianni, Marco Colleoni, Giancarlo Bisagni, et al.
The Breast Journal|February 28, 2019
Single Institution trial of anthracycline- and taxane-based chemotherapy for operable breast cancer: The ASTER studyGabriella Mariani, Giulia Galli, Stefano Cavalieri, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 13, 2012
Bortezomib plus dexamethasone followed by escalating donor lymphocyte infusions for patients with multiple myeloma relapsing or progressing after allogeneic stem cell transplantationVittorio Montefusco, Francesco Spina, Francesca Patriarca, et al.
Blood|May 10, 2003
Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myelomaPaolo Corradini, Michele Cavo, Henk Lokhorst, et al.
Pageof 6